---
title: PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
date: '2024-07-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38952399/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240703181944&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor (CAR)-T cell-based immunotherapy has emerged
  as a path-breaking strategy for certain hematological malignancies. Assessment of
  the response to CAR-T therapy using quantitative imaging techniques such as positron
  emission tomography/computed tomography (PET/CT) has been broadly investigated.
  However, the definitive role of PET/CT in CAR-T therapy remains to be established.
  [^(18)F]FDG PET/CT has demonstrated high sensitivity and specificity for differentiating
  ...
disable_comments: true
---
Chimeric antigen receptor (CAR)-T cell-based immunotherapy has emerged as a path-breaking strategy for certain hematological malignancies. Assessment of the response to CAR-T therapy using quantitative imaging techniques such as positron emission tomography/computed tomography (PET/CT) has been broadly investigated. However, the definitive role of PET/CT in CAR-T therapy remains to be established. [^(18)F]FDG PET/CT has demonstrated high sensitivity and specificity for differentiating ...